The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
 
Federico Innocenti
Consulting or Advisory Role - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Royalties from the Mayo Foundation on the UGT1A1 testing
 
Kouros Owzar
Patents, Royalties, Other Intellectual Property - Duke University
 
Chen Jiang
No Relationships to Disclose
 
Alexander Sibley
No Relationships to Disclose
 
Donna Niedzwiecki
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Merck Serono; Roche Pharma AG
Consulting or Advisory Role - Merck Serono; Roche Pharma AG
Research Funding - Merck Serono; Roche Pharma AG
Travel, Accommodations, Expenses - Merck Serono; Roche Pharma AG
 
Monica M. Bertagnolli
No Relationships to Disclose
 
Paula N. Friedman
No Relationships to Disclose
 
Yoichi Furukawa
Research Funding - Otsuka
 
Michiaki Kubo
No Relationships to Disclose
 
Mark J. Ratain
Stock and Other Ownership Interests - AspenBio Pharma; Biscayne Pharmaceuticals
Consulting or Advisory Role - AbbVie; Agios; Biscayne Pharmaceuticals; Cantex Pharmaceuticals; Cerulean Pharma; Cyclacel; Daiichi Sankyo; EMD Serono; Genentech/Roche; Kinex; Onconova Therapeutics; Sanofi; Shionogi; XSpray Microparticles AB
Research Funding - Bristol-Myers Squibb (Inst); Dicerna (Inst); OncoTherapy Science (Inst); PharmaMar (Inst)
Patents, Royalties, Other Intellectual Property - pending patent related to a genomic prescribing system; pending patent related to a genomic prescribing system (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - Apotex; Fresenius Kabi; Mylan; Teva
 
Charles David Blanke
Travel, Accommodations, Expenses - Novartis
 
Alan P. Venook
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Onyx (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Halozyme; Merck Serono; Roche
 
Howard L. McLeod
Consulting or Advisory Role - Cancer Genetics; Gentris; NIH/NCI; Saladax Biomedical